Interview with Marko Dolzan, President, Polfa Lodz
You were the CEO for three different companies and the founder of Sensilab and then you acquired Polfa Lodz. Could you relate to our readers the development of your career…
Address: ul. Drewnowska 43/55, 91-002 Lodz
Tel: +48 42 654 00 70
Web: http://www.polfa-lodz.com/
For 75 years, we have been specialising in producing top quality medicinal products, dietary supplements and cosmetics. Thanks to the trust of physicians and pharmacists, our products can be found in every Polish home.
Our strongest desire is to perfect our preparations and to make efforts to increase their safety and efficacy. We are constantly striving to maintain the highest production standards – our production processes comply with GMP, HACCP and ISO standards.
In order to maintain continuous development, we merged with SENSILAB Sp. z o.o. in 2008.
We are one of the leading drugs and dietary supplements manufacturers in Poland. Every year over 5,000,000 packets of our products are shipped to our customers. We offer over 50 different preparations. We are a leading manufacturer of calcium preparations based on the most easily absorbable form of calcium.
We are a pharmaceutical manufacturer which – apart from producing its own preparations – also provides contracted production services. Depending on the demand, our R&D department can develop products to be manufactured under a customer’s brand name. Owing to our modern and highly efficient equipment, we can fulfil your orders promptly. We take production services for our partners very seriously. We treat every enquiry on an individual basis, which results in the comprehensive service that our company can offer.
You were the CEO for three different companies and the founder of Sensilab and then you acquired Polfa Lodz. Could you relate to our readers the development of your career…
“We have made some progress in terms of the conceptualization of depression as a disease. Previously, the popular attitude was that depression was a temporary emotion; one that could be…
IMS’ General Manager, Maciej Kuzmierkiewicz, discusses the effects of the Reimbursement Act—the new legislative framework implemented in January 2012—which completely reshaped the rules of the game for the Polish pharmaceutical sector…
You have been heading the affiliate since its creation in 1997; therefore you saw its evolution and growth. Would you say that Apotex Poland has evolved in accordance with the…
You have been heading the affiliate since its creation in 1997; therefore you saw its evolution and growth. Would you say that Apotex Poland has evolved in accordance with the…
You have been quite recently appointed at the head of the Polish affiliate of AstraZeneca. With which personal ambitions did you come and what was the mission you were given…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable. The market size is over 5 billion Euros which makes Poland the 6th biggest market…
You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother…
BAUSCH + LOMB has over 150 years of heritage and has always been associated with optics and ophthalmology. Therefore the company has been able to build a very strong brand…
Given Cegedim’s global reach and your 13 year experience of operating as a consultant to the Polish pharma industry, how would you describe the market to the international readers of…
As Squibb Corporation and Bristol-Myers merged in 1989, Bristol-Myers Squibb has been officially operating in this market since that date, but the affiliate has a long history previous to that.…
Would you begin by explaining to the readers of Pharmaceutical Executive the importance of the operation in Poland for the company? Indeed Poland because of largest in CEE pharmaceutical market…
Firstly, what attracted you to join the CRO industry with Quintiles over 10 years ago? I had been working for 5 years as a doctor in the internal medicine and…
See our Cookie Privacy Policy Here
